Last reviewed · How we verify
Oral P2Y12 receptor blocker
This is an oral P2Y12 receptor antagonist marketed by the Italian Society of Invasive Cardiology for prevention of atherothrombotic events in acute coronary syndrome and myocardial infarction patients. The drug reduces thrombotic cardiovascular events across atherosclerotic disease populations including recent ischemic stroke and peripheral artery disease. With 4 clinical trials and 2 publications supporting its use, this represents a mature marketed therapy in the antiplatelet class. P2Y12 inhibitors are standard-of-care dual antiplatelet therapy components, though specific commercial differentiation depends on pharmacokinetic profile and clinical outcomes data. The drug addresses a large cardiovascular market with established clinical utility and regulatory approval.
At a glance
| Generic name | Oral P2Y12 receptor blocker |
|---|---|
| Sponsor | Italian Society of Invasive Cardiology |
| Drug class | Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class |
| Target | P2Y12 adenosine diphosphate receptor on platelet surface |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI)
- Reduction of thrombotic cardiovascular events in patients with atherosclerotic disease, including those with a recent ischemic stroke or peripheral artery disease (PAD)
Common side effects
Drug interactions
- Aspirin
- Warfarin
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Selective serotonin reuptake inhibitors (SSRIs)
- CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
- CYP3A4 inducers (e.g., rifampin, carbamazepine)
Key clinical trials
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome (PHASE4)
- Customized Choice of Oral P2Y12 Receptor Blocker (PHASE4)
- Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral P2Y12 receptor blocker CI brief — competitive landscape report
- Oral P2Y12 receptor blocker updates RSS · CI watch RSS
- Italian Society of Invasive Cardiology portfolio CI